|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,669.50 INR | +0.37% |
|
+1.92% | +2.96% |
| 06-02 | Alkem Laboratories Limited Launches Semaglutide in Single-Shot Pre-Filled Syringes At Price Starting Inr 350 | CI |
| 06-02 | Alkem Laboratories Shows Strong Moves But Weak Follow-Through |  |
Company Valuation: Alkem Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 331,171 | 432,909 | 406,055 | 590,890 | 583,680 | 677,874 | - | - |
| Change | - | 30.72% | -6.2% | 45.52% | -1.22% | 16.14% | - | - |
| Enterprise Value (EV) 1 | 328,603 | 433,805 | 393,853 | 587,236 | 578,678 | 632,481 | 656,141 | 642,765 |
| Change | - | 32.02% | -9.21% | 49.1% | -1.46% | 9.3% | 0.99% | -2.04% |
| P/E | 20.9x | 26.3x | 41.3x | 32.9x | 27x | 27.5x | 29x | 25.3x |
| PBR | 4.49x | 5.01x | 4.49x | 5.73x | 4.87x | 4.58x | 4.4x | 3.89x |
| PEG | - | 6.89x | -1x | 0.4x | 1.3x | 4.37x | -3.82x | 1.7x |
| Capitalization / Revenue | 3.74x | 4.07x | 3.5x | 4.66x | 4.5x | 4.31x | 4.1x | 3.72x |
| EV / Revenue | 3.71x | 4.08x | 3.4x | 4.64x | 4.46x | 4.3x | 3.97x | 3.53x |
| EV / EBITDA | 16.9x | 21.1x | 24.5x | 26.2x | 23x | 21x | 19.3x | 16.6x |
| EV / EBIT | 19.7x | 24.8x | 30.3x | 30.2x | 26.9x | 24.1x | 22.1x | 18.9x |
| EV / FCF | 30.4x | 55.4x | 27.1x | 33.3x | 45.3x | 42.8x | 36.2x | 30.9x |
| FCF Yield | 3.29% | 1.81% | 3.69% | 3% | 2.21% | 2.33% | 2.76% | 3.24% |
| Dividend per Share 2 | 28 | 34 | 25 | 40 | 45 | 53 | 51.35 | 56.59 |
| Rate of return | 1.01% | 0.94% | 0.74% | 0.81% | 0.92% | 1% | 0.91% | 1% |
| EPS 2 | 132.6 | 137.6 | 82.31 | 150.2 | 181.1 | 192.5 | 195.3 | 224.3 |
| Distribution rate | 21.1% | 24.7% | 30.4% | 26.6% | 24.8% | 27.5% | 26.3% | 25.2% |
| Net sales 1 | 88,650 | 106,342 | 115,993 | 126,676 | 129,645 | 147,123 | 165,307 | 182,166 |
| EBITDA 1 | 19,424 | 20,529 | 16,094 | 22,455 | 25,122 | 30,052 | 34,011 | 38,779 |
| EBIT 1 | 16,678 | 17,490 | 12,990 | 19,462 | 21,550 | 26,232 | 29,653 | 34,085 |
| Net income 1 | 15,850 | 16,456 | 9,842 | 17,958 | 21,655 | 23,018 | 23,589 | 27,377 |
| Net Debt 1 | -2,568 | 896.1 | -12,202 | -3,654 | -5,003 | -1,094 | -21,733 | -35,109 |
| Reference price 2 | 2,769.80 | 3,620.70 | 3,396.10 | 4,942.00 | 4,881.70 | 5,669.50 | 5,669.50 | 5,669.50 |
| Nbr of stocks (in thousands) | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | - | - |
| Announcement Date | 5/25/21 | 5/13/22 | 5/19/23 | 5/29/24 | 5/29/25 | 5/28/26 | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 26.82x | 4.44x | 21.48x | 0.95% | 7.11B | |
| 34.92x | 12.63x | 25.81x | 0.57% | 1,060B | |
| 27.42x | 6.3x | 17.1x | 2.08% | 619B | |
| 30x | 7.34x | 15.02x | 2.76% | 438B | |
| 17.98x | 4.45x | 11.01x | 2.97% | 333B | |
| 21.52x | 5.52x | 13.36x | 2.86% | 282B | |
| 21.56x | 4.53x | 12.65x | 1.94% | 267B | |
| 14.17x | 5.3x | 10.9x | 3.52% | 218B | |
| 23.77x | 6.31x | 11.12x | 2.78% | 196B | |
| -46.02x | 5.6x | 31.12x | 2.5% | 161B | |
| Average | 17.21x | 6.24x | 16.96x | 2.29% | 358.1B | |
| Weighted average by Cap. | 23.86x | 7.84x | 18.17x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALKEM Stock
- Valuation Alkem Laboratories Limited
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
